Antineutrophil cytoplasmic antibody-associated vasculitides

Joint Bone Spine

Volumn 74, Issue 5, 2007, Pages 427-435

  Puéchal, Xavier ^a  

^a CENTRE HOSPITALIER DU MANS   (France)

Author keywords

Antineutrophil cytoplasmic antibody; Churg Strauss syndrome; Microscopic polyangiitis; Vasculitis; Wegener granulomatosis

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DISEASE COURSE; EMERGENCY TREATMENT; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LABORATORY DIAGNOSIS; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; PLASMAPHERESIS; PROGNOSIS; RECURRENCE RISK; REMISSION; SHORT SURVEY; SURVIVAL; UNSPECIFIED SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CYCLOSPORINE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS; NEUTROPHILS; PLASMA EXCHANGE; VASCULITIS;

EID: 35348836590     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2007.02.001     Document Type: Short Survey

References (63)

1. Jennette J.C., Falk R.J., Andrassy K., Bacon P.A., Churg J., Gross W.L., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37 (1994) 187-192
2. Watts R.A., and Scott D.G. Epidemiology of the vasculitides. Semin Respir Crit Care Med 25 (2004) 455-464
3. Hoffman G.S., and Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 41 (1998) 1521-1537
4. Bosch X., Guilabert A., and Font J. Antineutrophil cytoplasmic antibodies. Lancet 368 (2006) 404-418
5. Savige J., Gillis D., Benson E., Davies D., Esnault V., Falk R.J., et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 111 (1999) 507-513
6. Savige J., Dimech W., Fritzler M., Goeken J., Hagen E.C., Jennette J.C., et al. International group for consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Addendum to the international consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 120 (2003) 312-318
7. Schmitt W.H., and van der Woude F.J. Clinical applications of antineutrophil cytoplasmic antibody testing. Curr Opin Rheumatol 16 (2004) 9-17
8. Tervaert J.W., Huitema M.G., Hené R.J., Sluiter W.J., The T.H., van der Hem G.K., et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 336 (1990) 709-711
9. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116 (1992) 488-498
10. Anderson G., Coles E.T., Crane M., Douglas A.C., Gibbs A.R., Geddes D.M., et al. Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med 83 (1992) 427-438
11. Matteson E.L., Gold K.N., Bloch D.A., and Hunder G.G. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am J Med 101 (1996) 129-134
12. Guillevin L., Cordier J.F., Lhote F., Cohen P., Jarrousse B., Royer I., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 40 (1997) 2187-2198
13. Reinhold-Keller E., Beuge N., Latza U., de Groot K., Rudert H., Nolle B., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43 (2000) 1021-1032
14. Serra A., Cameron J.S., Turner D.R., Hartley B., Ogg C.S., Neild G.H., et al. Vasculitis affecting kidney: presentation, histopathology and long-term outcome. Q J Med 53 (1984) 181-207
15. Savage C.O., Winearls C.G., Evans D.J., Rees A.J., and Lockwood C.M. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 56 (1985) 467-483
16. D'Agati V., Chander P., Nash M., and Mancilla-Jimenez R. Idiopathic microscopic polyarteritis nodosa: ultrastructural observations on the renal vascular and glomerular lesions. Am J Kidney Dis 7 (1986) 95-110
17. Adu D., Howie A.J., Scott D.G., Bacon P.A., McGonigle R.J., and Micheal J. Polyarteritis and the kidney. Q J Med 62 (1987) 221-237
18. Guillevin L., Durand-Gasselin B., Cevallos R., Gayraud M., Lhote F., Callard P., et al. Microscopic polyangiitis: clinical and laboratory findings in 85 patients. Arthritis Rheum 42 (1999) 421-430
19. Chumbley L., Harrison E., and DeRemee R. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Mayo Clin Proc 52 (1977) 477-484
20. Lanham J., Elkon K., Pusey C., and Hughes G. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 63 (1984) 65-81
21. Gaskin G., Ryan J., Rees A., and Pusey C. Antimyeloperoxydase antibodies in vasculitis. Relationship to ANCA and clinical diagnosis. Acta Pathol Microbiol Immunol Scand 98 S19 (1990) 33
22. Abu-Shakra M., Smythe H., Lewtas J., Badley E., Weber D., and Keystone E. Outcome of polyarteritis nodosa and Churg-Strauss syndrome. Arthritis Rheum 37 (1994) 1798-1803
23. Schnabel A., Hauschild S., and Gross W.L. Anti-neutrophil cytoplasmic antibodies in generalized autoimmune diseases. Int Arch Allergy Immunol 109 (1996) 201-206
24. Reid A.J., Harrison B.D., Watts R.A., Watkin S.W., McCann B.G., and Scott D.G. Churg-Strauss syndrome in a district hospital. Q J Med 91 (1998) 219-229
25. Guillevin L., Cohen P., Gayraud M., Lhote F., Jarrousse B., and Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78 (1999) 26-37
26. Solans R., Bosch J.A., Pérez-Bocanegra C., Selva A., Huguet P., Alijotas J., et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology 40 (2001) 763-771
27. Haas C., Le Jeunne C., Choubrac P., Durand H., and Hugues F.C. [Churg-Strauss syndrome. Retrospective study of 20 cases]. Bull Acad Natl Med 185 (2001) 1113-1130
28. Della Rossa A., Baldini C., Tavoni A., Tognetti A., Neglia D., Sambuceti G., et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology (Oxford) 41 (2002) 1286-1294
29. Keogh K.A., and Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 115 (2003) 284-290
30. Sablé-Fourtassou R., Cohen P., Mahr A., Pagnoux C., Mouthon L., Jayne D., et al. for the French Vasculitis Study Group. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143 (2005) 632-638
31. Sinico R.A., Di Toma L., Maggiore U., Bottero P., Radice A., Tosoni C., et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52 (2005) 2926-2935
32. Leavitt R.Y., Fauci A.S., Bloch D.A., Michel B.A., Hunder G.G., Arend W.P., et al. The American college of rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33 (1990) 1101-1107
33. Masi A.T., Hunder G.G., Lie J.T., Michel B.A., Bloch D.A., Arend W.P., et al. The American college of rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33 (1990) 1094-1100
34. Luqmani R., Exley A., Kitas G., and Bacon P. Disease assessment and management of the vasculitides. Bailliere's Clin Rheum 11 (1997) 423-446
35. Exley A.R., Carruthers D.M., Luqmani R.A., Kitas G.D., Gordon C., Janssen B.A., et al. Damage occurs early in systemic vasculitis and is an index of outcome. Q J Med 90 (1997) 391-399
36. Jayne D., Rasmussen N., Andrassy K., Bacon P., Tervaert J.W., Dadoniene J., et al. European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 (2003) 36-44
37. Pagnoux C., Mahr A., Cohen P., Arène J.P., Hamidou M., Cordier J.F., et al. for the French Vasculitis Study Group (FVSG). Treatment of ANCA-associated systemic vasculitides with pulse cyclophosphamide then azathioprine versus methotrexate to maintain remission: Interim analysis of a prospective, randomized, multicenter trial. [abstract]. Arthritis Rheum 9 (2003) 660
38. Stegeman C.A., Tervaert J.W., Sluiter W.J., Manson W.L., de Jong P.E., and Kallenberg C.G. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120 (1994) 12-17
39. Guillevin L., Lhote F., Gayraud M., Cohen P., Jarrousse B., Lortholary O., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75 (1996) 17-28
40. Gayraud M., Guillevin L., le Toumelin P., Cohen P., Lhote F., Casassus P., et al. French Vasculitis Study Group. Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44 (2001) 666-675
41. De Groot K., Rasmussen N., Bacon P.A., Tervaert J.W., Feighery C., Gregorini G., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 2461-2469
42. Cohen P., Pagnoux C., Mahr A., Mouthon L., Puéchal X., Le Guern V., et al. for the French Vasculitis Study Group (FVSG). Treatment of non-HBV polyarteritis nodosa and microscopic polyangiitis with corticosteroids alone. Preliminary results of a prospective, multicenter trial in France. [abstract]. Arthritis Rheum 47 (2003) 453
43. Cohen P., Mouthon L., Godmer P., André M.H., Ramanoelina J., Arène J.P., et al. for the French Vasculitis Study Group. Corticosteroids alone for Churg-Strauss syndrome without initial poor prognostic factor (five factor score (FFS) = 0). Preliminary results at 4 years of a French multicenter prospective study. [abstract]. Arthritis Rheum 44 (2001) 56
44. Haubitz M., Schellong S., Gobel U., Schurek H.J., Schaumann D., Koch K.M., et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement. A prospective, randomized study. Arthritis Rheum 41 (1998) 1835-1844
45. de Groot K., Adu D., Savage C.O., and EUVAS (European Vasculitis Study Group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16 (2001) 2018-2027
46. de Groot K, Jayne D, Tesar V, Savage C. Randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis, in press.
47. Gaskin G, Jayne D. Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis, in press.
48. Jayne D.R., Chapel H., Adu D., Misbah S., O'Donoghue D., Scott D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 93 (2000) 433-439
49. Langford C.A., Talar-Williams C., Barron K.S., and Sneller M.C. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 42 (1999) 2666-2673
50. Langford C.A., Talar-Williams C., Barron K.S., and Sneller M.C. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 114 (2003) 463-469
51. Keogh K.A., Wylam M.E., Stone J.H., and Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 262-268
52. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257 (2005) 540-548
53. Omdal R., Wildhagen K., Hansen T., Gunnarsson R., and Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 34 (2005) 229-232
54. Gottenberg J.E., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., et al. for the Club Rhumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64 (2005) 913-920
55. Smith K.G., Jones R.B., Burns S.M., and Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54 (2006) 2970-2982
56. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., and Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173 (2006) 180-187
57. Aries P.M., Hellmich B., Voswinkel J., Both M., Nolle B., Holl-Ulrich K., et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65 (2006) 853-858
58. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41 (2002) 1126-1132
59. Lamprecht P., Voswinkel J., Lilienthal T., Nolle B., Heller M., Gross W.L., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41 (2002) 1303-1307
60. Booth A.D., Jefferson H.J., Ayliffe W., Andrews P.A., and Jayne D.R. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 61 (2002) 559
61. Booth A., Harper L., Hammad T., Bacon P., Griffith M., Levy J., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15 (2004) 717-721
62. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351-361
63. Stegeman C.A., Tervaert J.W., de Jong P.E., and Kallenberg C.G. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-trimoxazole Wegener Study Group. N Engl J Med 335 (1996) 16-20